Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database

Documenti analoghi

• Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
  di: Siyue Chen, et al.
  Pubblicazione: (2024)
• Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database
  di: Qining He, et al.
  Pubblicazione: (2025)
• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  di: Yuji Kumagai, et al.
  Pubblicazione: (2025)
• Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases
  di: Henning Olbrich, et al.
  Pubblicazione: (2026)
• Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
  di: Yue Wu, et al.
  Pubblicazione: (2024)